Method for enzymatic treatment of tissue products
View Patent ↗Methods for treating tissue matrices and tissue matrices produced according to the methods are provided. The methods can include treating a tissue matrix with a proteolytic enzyme to produce a desired pliability of the tissue matrix and/or to control the immunogenicity of the tissue matrix. The methods can also comprise performing an assay to determine if contacting the at least one collagen-containing tissue matrix with a proteolytic enzyme has altered the at least one collagen-containing tissue matrix to reduce a human immune response to the tissue matrix. The methods can comprise treatment with alcalase under conditions controlled to produce a desired pliability without unacceptable alteration in collagen structure.
1. A method for treating a tissue matrix, comprising:
selecting a dermal tissue;
contacting the dermal tissue with a first solution comprising an effective amount of alcalase under conditions including an incubation time in the first solution having an alcalase activity selected to produce an increase in pliability of the dermal tissue without producing significant collagen degradation to produce an alcalase-treated dermal tissue; and
treating the alcalase-treated dermal tissue with a second solution to decellularize the alcalase-treated dermal tissue to produce an acellular dermal tissue matrix, wherein the pliability can be measured by a drape test of the acellular dermal tissue matrix.
2. The method of claim 1 , wherein the dermal tissue is a non-primate tissue.
3. The method of claim 1 , wherein the dermal tissue is a porcine tissue.
4. The method of claim 1 , wherein the first solution comprises alcalase with an activity of 1×10 −6 Anson units/mL to 0.015 Anson units/mL.
5. The method of claim 1 , wherein the first solution comprises alcalase with an activity of 1×10 −6 Anson units/mL to 1.5×10 −3 Anson units/mL.
6. The method of claim 1 , wherein the first solution comprises alcalase with an activity of about 2×10 −5 Anson units/mL to about 4×10 −5 Anson units/mL.
7. The method of claim 1 , further comprising packaging the dermal tissue matrix.
8. The method of claim 1 , further comprising sterilizing the dermal tissue matrix.
9. The method of claim 1 , wherein the dermal tissue is contacted with alcalase under conditions to produce reductions in the drape value of or at least 30%.
10. The method of claim 1 , wherein the dermal tissue is contacted with alcalase under conditions to produce reductions in the drape value of or at least 40%.
11. The method of claim 1 , wherein the dermal tissue is contacted with alcalase under conditions to produce reductions in the drape value of or at least 50%.
12. The method of claim 1 , wherein the dermal tissue is contacted with alcalase under conditions to produce reductions in the drape value of or at least 60%.
13. The method of claim 1 , wherein the dermal tissue is contacted with alcalase under conditions to produce a drape value of 0.2-0.4.
14. The method of claim 1 , wherein the drape test comprises placing the acellular dermal tissue matrix of a known circular area on top of a circular pedestal having a known diameter and dividing the projected area of the acellular dermal tissue matrix after it drapes over the pedestal by the original area of the tissue matrix circle to determine the drape value.